


## SUPPLEMENTARY TABLES AND FIGURES



**Supplementary Figure S1: Kaplan–Meier plot of Overall Survival for 133 Liver Hepatocellular Carcinoma from publicly available TCGA data at cBioPortal stratified by level of BRF1 expression.** The Brf1 expression level z-score cut-off used for dividing the cases with high expression of Brf1 from the cases with low expression of Brf1. n = number of patients in the subgroup, M = median survival in months of the subgroup.

**Supplementary Table S1: Characteristics of 133 HCC patients**

Characteristics	HCC patients(N = 133)
Sex	
Female	21
Male	112
Age(years)	
≤50	62
> 50	71
Follow-up time(month)	
Median(range)	12(75)
Tumor size stage	
T1+T2	86
T3a+T3b	46
Clinical stage	
I+II	86
III+IV	46

**Supplementary Table S2: Association between BRF1 expression and clinicopathologic characteristics of patients with HCC (*n* = 133)**

Clinical features	Number	BRF1 (-)	BRF1 (+)	P-value
Gender				0.279
Female	21	3	18	
Male	112	32	80	
Age (yrs)				0.63
< 50	62	15	47	
> 50	71	20	51	
HbsAg				0.187
Negative	22	3	19	
Positive	111	32	79	
Serum AFP (ng/ml)				0.028
< 400	76	26	50	
> 400	56	9	47	
Serum ALT				0.559
< 40	70	17	53	
> 40	62	18	44	
Tumor size (cm)				1.00
< 5	47	12	35	
> 5	86	23	62	
Recurrence				0.554
Absent	68	20	48	
Present	64	15	49	
TNM stage (AJCC)				0.218
Early (I-II)	86	26	60	
Advanced(III-IV)	46	9	37	

**Supplementary Table S3: siRNA targets**

Targets	Sequences
Mismatch	sense 5'UUC UCC GAA CGU GUC ACG Utt 3' antisense 5'ACG UGA CAC GUU CGG AGA Att 3'
Mouse Brf1 siRNA (1)	<b>A:</b> sense 5' ACC UUG AGA UUG ACA GAU A dTdT 3'; antisense 5' UAU CUG UCA AUC UCA AGG UdTdT 3'; <b>B:</b> sense 5' AAG CAC UGC CCC ACU UAU UUG dTdT 3'; antisense 5' CAA AUA AGU GGG GCA GUG CUU dTdT 3'; <b>C:</b> sense: 5' AAG CAC UGC CCC ACU UAU UUG dTdT 3' antisense: 5' CAA AUA AGU GGG GCA GUG CUU dTdT3'
Human Brf1 siRNA (2)	<b>A:</b> sense 5' GGA AGA UCU GUU GUU ACU U 3' antisense 5' AAG UAA CAA CAG AUC UUC C 3' <b>B:</b> sense 5' CCC GUG CCU GUA UAU UCC A 3' antisense 5' UGG AAU AUA CAG GCA CGG G 3' <b>C:</b> sense 5' GAG CAU AGC GCC AGU GCC A 3' antisense 5' UGG CAC UGG CGC UAU GCU C 3'

**Supplementary Table S4: Primer Sets for Quantitative RT-PCR**

Target	Primers	Annealing Temperature
Pre-tRNA <sup>Leu</sup> (3)	(F) 5'-GTC AGG ATG GCC GAG TGG TCT AAG-3' (R) 5'-CCA CGC CTC CAT ACG GAG AAC CAG AAG ACC C-3'	61°
5S rRNA (4)	(F) 5' GGC CAT ACC ACC CTG AAC GC 3' (R) 5' CAG CAC CCG GTA TTC CCA GG 3'	61°
Mouse Brf1(4) Human Brf1 (4)	(F) 5' GGA GCA GAG CCA ATC AAG CCA -3' (R) 5' CAT CAC CAT CAC AGC CGT AAT C -3' (F) 5' CCT CGG GCC TCT GCG GAG CAG -3' (R) 5' TCA TCA ATG GTC AAC TGA CTG GTG G -3'	62° 60°
GAPDH (4)	(F) 5'-TCC ACC ACC CTG TTG CTG TA-3' (R) 5'-ACC ACA GTC CAT GCC ATC AC-3'	61°

Abbreviations: (F) = forward, (R) = reverse.

## SUPPLEMENTARY REFERENCES

1. Johnson SA and Johnson DL. Enhanced RNA polymerase III-dependent transcription is required for oncogenic transformation. *J Biol Chem.* 2008; 283:19184–19191.
2. Zhong Q, Shi G, Zhang Q, Zhang Y, Levy D, Zhong S. Role of phosphorylated histone H3 serine 10 in DEN-induced deregulation of Pol III genes and cell proliferation and transformation. *Carcinogenesis.* 2013; 34: 2460–2469.
3. Crighton, D., Woiwode, A., Zhang, C., Mandavia, N., Morton, J.P., Warnock, L.J. *et al.* p53 represses RNA polymerase III transcription by targeting TBP and inhibiting promoter occupancy by TFIIIB. *EMBO J.* 2003; 22: 2810–2820.
4. Zhong S. and Johnson DL. The JNKs differentially regulate RNA polymerase III transcription by coordinately modulating the expression of all TFIIIB subunits. *Proc Natl Acad Sci U S A.* 2009; 106:12682–12687.